- Home
- CMMB vs ZCMD Comparison
CMMB vs ZCMD Comparison
Compare CMMB & ZCMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- ZCMD
- Stock Information
- Founded
- CMMB 2004
- ZCMD 2012
- Country
- CMMB Israel
- ZCMD China
- Employees
- CMMB N/A
- ZCMD N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- ZCMD Other Consumer Services
- Sector
- CMMB Health Care
- ZCMD Real Estate
- Exchange
- CMMB Nasdaq
- ZCMD Nasdaq
- Market Cap
- CMMB 22.0M
- ZCMD 25.3M
- IPO Year
- CMMB N/A
- ZCMD 2020
- Fundamental
- Price
- CMMB $3.02
- ZCMD $0.96
- Analyst Decision
- CMMB Strong Buy
- ZCMD
- Analyst Count
- CMMB 2
- ZCMD 0
- Target Price
- CMMB $26.50
- ZCMD N/A
- AVG Volume (30 Days)
- CMMB 108.4K
- ZCMD 3.6K
- Earning Date
- CMMB 08-14-2025
- ZCMD 01-01-0001
- Dividend Yield
- CMMB N/A
- ZCMD N/A
- EPS Growth
- CMMB N/A
- ZCMD N/A
- EPS
- CMMB N/A
- ZCMD N/A
- Revenue
- CMMB N/A
- ZCMD $15,864,773.00
- Revenue This Year
- CMMB N/A
- ZCMD N/A
- Revenue Next Year
- CMMB N/A
- ZCMD N/A
- P/E Ratio
- CMMB N/A
- ZCMD N/A
- Revenue Growth
- CMMB N/A
- ZCMD N/A
- 52 Week Low
- CMMB $3.02
- ZCMD $0.86
- 52 Week High
- CMMB $10.20
- ZCMD $2.97
- Technical
- Relative Strength Index (RSI)
- CMMB 19.63
- ZCMD 46.85
- Support Level
- CMMB $3.32
- ZCMD $0.93
- Resistance Level
- CMMB $3.86
- ZCMD $1.07
- Average True Range (ATR)
- CMMB 0.28
- ZCMD 0.08
- MACD
- CMMB -0.03
- ZCMD 0.01
- Stochastic Oscillator
- CMMB 2.65
- ZCMD 47.62
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About ZCMD Zhongchao Inc.
ZHONGCHAO Inc is an offshore holding company incorporated in the Cayman Islands. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provide the healthcare information, education, and training services to the healthcare professionals under their MDMOOC brand. It also provide focused patient management services, through Zhongxun IT system and WeChat mini program and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.